Avéli versus Cellfina: what their FDA clearances actually compare
Both devices were cleared for the appearance of buttock and thigh cellulite in adult women. Their FDA summaries describe different devices and follow-up windows, not a head-to-head winner.
Avéli and Cellfina are FDA-cleared devices for improving the appearance of cellulite on the buttocks and thighs in adult women. Avéli’s later clearance supports a long-term appearance claim through one year; Cellfina’s clearance reports benefit through five years. These are separate study and labeling records, not a randomized comparison showing that Cellfina works better or lasts longer for a particular person.12
The question starts with what causes the visible dimple. Both devices are designed to release fibrous septa beneath the skin. That target differs from treating fat thickness, skin laxity, or a broad change in body shape. The cellulite mechanism guide helps separate those goals before comparing named devices.
Put the FDA records side by side
| Record | Avéli K221336 | Cellfina K192185 |
|---|---|---|
| FDA action | 510(k) clearance | 510(k) clearance |
| Tool | Single-use manual release tool with integrated light | Motorized reusable handpiece with single-use blade |
| Follow-up | Long-term improvement through one year | Long-term improvement through five years |
| Limit | No five-year Avéli evidence in this submission | Year-five sample is smaller than the original group |
Clearance means FDA found the device substantially equivalent to a legally marketed predicate for its stated use. It is not the same regulatory pathway as an FDA drug approval. The summaries specify adult female buttock and thigh cellulite, so a claim about another body area or another concern requires separate evidence.12
Avéli’s later K221336 clearance enrolled 74 people across nine sites in a prospective, nonrandomized, single-arm study after one treatment. Blinded photo review assessed appearance at three, six, and twelve months, supporting the one-year claim. A quote promising a fixed multi-year duration from that clearance would go beyond its observation window.1
Cellfina’s five-year result is also narrower than a blanket durability guarantee. The FDA summary reports 55 enrolled at baseline and 37 assessed at year five. The people available at later follow-up may differ from those lost to follow-up. The longer observation is valuable but does not replace a direct trial assigning similar patients to Cellfina versus Avéli.2
Compare the plan, not just the label horizon
A helpful consultation identifies the areas and dimples the practitioner believes are septa-driven, what the device is expected to change, and how photographs or a standardized scale would be used to assess the result. Ask how many areas are proposed, who performs the release, what follow-up is included, and which adverse events and limitations appear in the device information. A “five-year treatment” slogan skips the difference between population follow-up and an individual forecast.
The quote should state whether it covers one treatment, any separate area, facility charges, and follow-up. Our body-contouring quote framework explains why two prices may not describe the same scope. No published clearance sets a clinic price.
If the central concern is loose skin or overall body size, ask the provider to explain why septa release is the chosen mechanism before selecting either device. The body-contouring versus weight-loss distinction is useful here. Compare body-contouring practices to find a consultation, then ask for the exact device name and a goal-specific plan.
Read the adverse-event record without cross-trial arithmetic
Avéli’s K221336 summary reports bruising, tenderness, pain, induration and numbness among adverse events in its treated study group. Those categories are useful to ask about before a procedure. Their percentages should not be placed beside Cellfina percentages as if both trials enrolled identical participants, defined events identically, and observed them on the same schedule. The studies were not designed to compare adverse-event rates between these devices.12
A clear provider explanation will name expected local effects, the practice’s approach to an unexpected problem, and which device record it is using. It should also say whether any cited photograph comes from a study or from a particular practice. A study photo can show a possible appearance change; it does not set a personal probability. The evidence supports a careful comparison of claims, mechanism, population, and offered service, not a one-word winner.
Sources
- U.S. Food and Drug Administration. Avéli one-year 510(k) summary, K221336. Current long-term cellulite-appearance indication supported through one year; 74-person single-arm study and adverse-event summary. Accessed .
- U.S. Food and Drug Administration. Cellfina 510(k) summary, K192185. Describes powered subcision device and long-term appearance improvement through five years with 37 of 55 participants assessed at year five. Accessed .